InnoCan Pharma (INNPF) AI Stock Analysis

InnoCan Pharma

(Other OTC:INNPF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong Gross MarginsGross margins near 90% indicate favorable economics on the company’s formulated products and potential pharmaceutical offerings. If maintained as revenue scales, this profitability foundation can support research investment, commercial expansion, and eventual operating leverage despite current losses.

Negative Factors

Persistent UnprofitabilityInnoCan remains unprofitable, so its high gross margin has not yet translated into positive operating or shareholder returns. Continued losses reduce internally generated funding for development and increase the importance of successful execution and eventual earnings improvement.

InnoCan Pharma (INNPF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $5.80M
Dividend Yield: ―
Average Volume (3M): 128
Price to Earnings (P/E): -6.6
Beta (1Y): -0.35
Revenue Growth: -18.39%
EPS Growth: 39.79%
Country: US
Employees: 11
Sector: Consumer Defensive
Sector Strength: 62
Industry: Medical - Pharmaceuticals

InnoCan Pharma Business Overview & Revenue Model

Company Description

InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland...

InnoCan Pharma Peers Comparison

Overall Rating

UnderperformOutperform

Sector (62)

Financial Indicators

INNPF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
TSE:LABS	49Neutral	CAD 27.77M	-5.60	-13.79%	―	-6.74%	43.54%
TSE:ATLE	42Neutral	CAD 41.96M	-0.76	-2099.75%	―	-100.00%	94.43%
TSE:AVCN	41Neutral	CAD 14.11M	-3.24	-108.44%	―	-0.23%	-142.54%
TSE:VM	41Neutral	CAD 27.16M	-5.53	-403.29%	―	360.63%	14.21%

* Consumer Defensive Sector Average

Performance Comparison

INNPF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
INNPF	Innocan Pharma Corporation	1.32	-11.63	-89.80%
TSE:ATLE	Willow Biosciences	0.09	-0.08	-47.06%
TSE:LABS	Medipharm Labs (Otc)	0.07	-0.01	-7.14%
TSE:VM	Voyageur Pharmaceuticals Ltd.	0.12	-0.03	-20.00%
TSE:AVCN	Avicanna Inc	0.10	-0.14	-57.14%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

InnoCan Pharma AI Stock Analysis